Uniqure’s accelerated approval hopes take a hit
Despite showing arguable signals of efficacy Uniqure’s Huntington’s disease gene therapy has some fundamental problems.
Lilly signs up Verve to take on Novartis and Amgen
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Quanterix sees a bright future for blood biomarkers
A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
Astellas doesn’t buy Apellis
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.